Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

240 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
MERS-CoV‒Specific T-Cell Responses in Camels after Single MVA-MERS-S Vaccination.
Meyer Zu Natrup C, Schünemann LM, Saletti G, Clever S, Herder V, Joseph S, Rodriguez M, Wernery U, Sutter G, Volz A. Meyer Zu Natrup C, et al. Among authors: sutter g. Emerg Infect Dis. 2023 Jun;29(6):1236-1239. doi: 10.3201/eid2906.230128. Emerg Infect Dis. 2023. PMID: 37209676 Free PMC article.
MVA-based vaccine candidates encoding the native or prefusion-stabilized SARS-CoV-2 spike reveal differential immunogenicity in humans.
Mayer L, Weskamm LM, Fathi A, Kono M, Heidepriem J, Krähling V, Mellinghoff SC, Ly ML, Friedrich M, Hardtke S, Borregaard S, Hesterkamp T, Loeffler FF, Volz A, Sutter G, Becker S, Dahlke C, Addo MM. Mayer L, et al. Among authors: sutter g. NPJ Vaccines. 2024 Jan 26;9(1):20. doi: 10.1038/s41541-023-00801-z. NPJ Vaccines. 2024. PMID: 38278816 Free PMC article.
Dissecting humoral immune responses to an MVA-vectored MERS-CoV vaccine in humans using a systems serology approach.
Weskamm LM, Tarnow P, Harms C, Huchon M, Raadsen MP, Friedrich M, Rübenacker L, Grüttner C, Garcia MG; MVA-MERS-S-CEF study group; Koch T, Becker S, Sutter G, Lhomme E, Haagmans BL, Fathi A, Blois SM, Dahlke C, Richert L, Addo MM. Weskamm LM, et al. Among authors: sutter g. iScience. 2024 Jul 8;27(8):110470. doi: 10.1016/j.isci.2024.110470. eCollection 2024 Aug 16. iScience. 2024. PMID: 39148710 Free PMC article.
Safety, immunogenicity, and optimal dosing of a modified vaccinia Ankara-based vaccine against MERS-CoV in healthy adults: a phase 1b, double-blind, randomised placebo-controlled clinical trial.
Raadsen MP, Dahlke C, Fathi A, Hardtke S, Klüver M, Krähling V, Gerresheim GK, Mayer L, Mykytyn AZ, Weskamm LM, Zoran T, van Gorp ECM, Sutter G, Becker S, Haagmans BL, Addo MM; MVA-MERS-S_DF-1 Study group. Raadsen MP, et al. Among authors: sutter g. Lancet Infect Dis. 2024 Oct 7:S1473-3099(24)00423-7. doi: 10.1016/S1473-3099(24)00423-7. Online ahead of print. Lancet Infect Dis. 2024. PMID: 39389076
A Brighton collaboration standardized template with key considerations for a benefit/risk assessment for a viral vector vaccine based on a non-replicating modified vaccinia virus Ankara viral vector.
Link EK, Tscherne A, Sutter G, Smith ER, Gurwith M, Chen RT, Volz A; Benefit-Risk Assessment of VAccines by TechnolOgy Working Group (BRAVATO; ex-V3SWG). Link EK, et al. Among authors: sutter g. Vaccine. 2025 Jan 1;43(Pt 1):126521. doi: 10.1016/j.vaccine.2024.126521. Epub 2024 Nov 28. Vaccine. 2025. PMID: 39612556 Free article. Review.
Multi-omics characterization of the monkeypox virus infection.
Huang Y, Bergant V, Grass V, Emslander Q, Hamad MS, Hubel P, Mergner J, Piras A, Krey K, Henrici A, Öllinger R, Tesfamariam YM, Dalla Rosa I, Bunse T, Sutter G, Ebert G, Schmidt FI, Way M, Rad R, Bowie AG, Protzer U, Pichlmair A. Huang Y, et al. Among authors: sutter g. Nat Commun. 2024 Aug 8;15(1):6778. doi: 10.1038/s41467-024-51074-6. Nat Commun. 2024. PMID: 39117661 Free PMC article.
240 results